Navigation Links
Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
Date:9/3/2008

of the open-label, large sample, multi-center Endu phase IV clinical study affirms the safety and therapeutic efficacy of Endu acting in conjunction with platinum-based chemotherapy. With our continued research of Endu Phase IV, we will collect more clinical data to further evaluate the safety and efficacy of Endu."

To date, over 2,000 NSCLC patients have been recruited for Endu Phase IV clinical study. The final results of the study will be announced in the first half of 2010.

As a leading patented anti-cancer biotech product in China, Endu is recommended in the National Comprehensive Cancer Network of China Clinical Practice Guidelines in Oncology Chinese Version (2006-2008)as a first line treatment for NSCLC.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmac
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
2. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
3. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
4. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
11. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/27/2008)...ec. 23 Warner Chilcott L...of its subsidiaries and Mayne Pharma International...., have filed lawsuits against each of Mutual Phar...euticals Inc. ("Mylan") and Impax Laboratories, In...ct of New Jersey for infringement of Mayne,s U.S. ...
(Date:12/17/2008)...n development and validation of non-animal alterna...17 MatTek Corporation today announ...ESAC) endorsed the scientific validity of the Modi...ember meeting. ESAC concluded that the Modified E... for the prediction of skin irritating and non-irr...
(Date:12/17/2008)... PEAK Surgical, Inc., a medical,de...ction system based on a,proprietary technology, a...stration (FDA) has granted the company 510(k) clea...tting and coagulation of soft tissue during,plast... gynecologic,orthopedic, arthroscopic, spinal an...
(Date:12/17/2008)...e, December 17 NicOx,S....tive results of a,pre-specified pooled analysis o...e 301, 302 and 303 pivotal phase 3 studies for nap...ificant reduction in systolic and diastolic blood,...g bid over the whole 13 week,period (p<0.001 f...
Breaking Medicine Technology:Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 2NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 3NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 5June GEOSPHERE media highlights 3472 1June GEOSPHERE media highlights 3472 2June GEOSPHERE media highlights 3472 3June GEOSPHERE media highlights 3472 4Inflammation depression and antidepressant response 3A Common mechanisms 20582 1OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy 20578 1OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy 20578 2Certain Tests in ERs Raise Cancer Risk for Some 20575 1Certain Tests in ERs Raise Cancer Risk for Some 20575 2Certain Tests in ERs Raise Cancer Risk for Some 20575 3Certain Tests in ERs Raise Cancer Risk for Some 20575 4
(Date:1/8/2009)..., First Announced Acquisition in 2009 Continues G... IPC The Hospitalist Com...ospitalist physician group practice company, annou...actice of Midwest Acute Care Consultants, Inc. (MA...ents continued expansion in the St. Louis market, ...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-Asia/ -- ...HDX" or "the Company"), a leading independent Amer...services in the People,s Republic,of China, today...BS Greater,China Conference, to be held in Shangh... Greater China Conference will be held at the Pudo...
(Date:1/8/2009)..., ROCKVILLE, Md., Jan. 8 /PRNewswire-USNewswire/ ...ctives, advice and guidance on drugs, biological p...althcare Research and Quality,s Centers for Educat...lly sponsored network of more than a dozen leading...mer Health Advisory Information Network ( CHAIN ) ...
(Date:1/8/2009)..., FRAZER, Pa., Jan. 8 ...that Frank Baldino, Jr., Ph.D., Chairman and CEO w...nce, to be held on January 13, 2009 in San Francis...p.m. Eastern Time). The presentation will be webca...ompany,s website. , , The webcast will be arch...
Breaking Medicine News(10 mins):Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...ic and geographic data of the H5N1 avian flu virus...//They found that multiple strains of the virus or... they identified many of the migration routes thro...y and internationally. By knowing where H5N1 stra...
...ons of brain function in the field of conducting t...reparing to move when a traffic light turns green.... of psychology at the Georgia Institute of Technol... they conducted MRI brain scans of their subjects ...
...daily may have the potential to reverse impairment... to a first-of-its-kind study published in the Jou...d in the study was rich in flavanols, naturally-oc...ocoa prior to their destruction during the typical...
...netic roots of the most common form of amyotrophic...e newly identified 34 unique variations in the hum...ALS. The 34 so-called single nucleotide polymorp...e genes predisposing people to the noninherited fo...
Other Medicine News:Health News:UCI Scientists Reconstruct Migration of Avian Flu Virus 2Health News:Same Areas of the Brain Prepare for and Respond to a Stimulus, Say Experts 2Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 2Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 3Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 4Health News:Gene Hunters at Johns Hopkins Close In On Lou Gehrig's Disease 2
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
Medicine Products: